Immunospecific drug design--prospects for treatment of autoimmune diseases.
Recent advances in elucidating the activation and regulation of the autoimmune processes have provided new approaches for selective immunotherapy. Three different strategies are described: autoantigen-based therapy utilizing immunospecifically designed macromolecules and peptides, T-suppressor lines and clones, as well as antibodies specific to the antigen-MHC complex. These modalities, the efficacy of which has been demonstrated for experimental allergic encephalomyelitis, may be adapted to other experimental as well as human autoimmune diseases.
Arnon
R
R
Department of Chemical Immunology, Weizmann Institute of Science, Rehovot, Israel.
Teitelbaum
D
D
D000818:Animals; D001324:Autoantigens / Q000737:chemistry; D001327:Autoimmune Diseases / Q000628:therapy*; D015195:Drug Design; D004681:Encephalomyelitis, Autoimmune, Experimental / Q000628:therapy; D006801:Humans; D008285:Major Histocompatibility Complex; D051379:Mice; D011948:Receptors, Antigen, T-Cell / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology; D050378:T-Lymphocytes, Regulatory / Q000276:immunology
D001324:Autoantigens; D011948:Receptors, Antigen, T-Cell